0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Seasonal Influenza Vaccines Market Research Report 2025
Published Date: 2025-12-26
|
Report Code: QYRE-Auto-21W6969
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Seasonal Influenza Vaccines Market Insights and Forecast to 2028
BUY CHAPTERS

Global Seasonal Influenza Vaccines Market Research Report 2025

Code: QYRE-Auto-21W6969
Report
2025-12-26
Pages:121
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Seasonal Influenza Vaccines Market Size

The global market for Seasonal Influenza Vaccines was valued at US$ 9135 million in the year 2024 and is projected to reach a revised size of US$ 13501 million by 2031, growing at a CAGR of 5.5% during the forecast period.

Seasonal Influenza Vaccines Market

Seasonal Influenza Vaccines Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Seasonal Influenza Vaccines competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Seasonal Influenza Vaccines are prophylactic biological products formulated each season to target influenza A and B strains that are circulating or predicted to circulate. By delivering specific viral surface antigens or genetic instructions encoding these antigens (through protein subunits, recombinant platforms, or mRNA), these vaccines stimulate neutralizing antibodies and cellular immunity to reduce infection, severe disease, and complications. Contemporary seasonal influenza vaccines span multiple technology platforms — traditional egg-based/inactivated formulations, cell-based production, recombinant protein technologies, and the emergent mRNA platform. Given antigenic drift of influenza viruses, annual public-health prioritization, and shifting government immunization programs, seasonal influenza vaccines serve both as a public-health staple and a strategic, value-generating product category for vaccine firms pursuing technological upgrades, capacity coordination, and public-sector partnerships.In 2024, global In 2024, global Flu (Influenza) Vaccine production reached approximately 845.8 m units, with an average global market price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%. production reached approximately 845.8 m units, with an average global market price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%.
Against a background of strengthened public-health systems and rapid vaccine-technology advances, the seasonal influenza vaccine market faces structural growth opportunities. Governments are continuously improving annual influenza protection strategies, expanding priority-group coverage, and enhancing surveillance systems—providing policy-backed demand. Technological progress—especially the commercialization of cell-based platforms, recombinant protein approaches and mRNA technology—improves antigen matching, production control and speed of response to emerging strains, reshaping product portfolios and supply capabilities. Leading companies’ epidemiology and impact reports repeatedly highlight the direct benefits of increased vaccination in reducing hospitalizations and healthcare strain; from a corporate perspective, strengthening technological capabilities and supply reliability unlocks opportunities in both public procurement and private markets.
Growth is constrained by rising regulatory expectations, the inherent uncertainty of annual strain selection, and the capital- and compliance-intensive nature of large-scale production. Regulators are increasing requirements for batch consistency, demonstrated protection, and rapid traceability, pushing up R&D and quality-system costs. Egg-based production still dominates in several regions, exposing upstream supply chains to seasonal and regional vulnerabilities for eggs, media and critical reagents. Industry consolidation further raises barriers to entry, making negotiation power and channel access more difficult for smaller players. Corporate annual reports underscore that weaknesses in any corner of the “capital–compliance–capacity” triangle can amplify commercial risk.
Downstream demand shows a dual pattern of “normalization plus premiumization”: aging populations, rising chronic-disease prevalence and improved public awareness are shifting vaccination from event-driven to routine protection. Buyers increasingly demand differentiated products (e.g., formulations optimized for vulnerable populations or enhanced breadth) and guaranties of supply stability, steering the market toward “functional products + contracted supply.” Government procurement, insurance coverage and corporate vaccination programs are key drivers of coverage; digital booking systems, expanded primary-care networks and large-scale institutional partnerships provide scalable distribution channels and brand-building opportunities. Overall, downstream is evolving from pure volume replacement toward long-term cooperation emphasizing quality, delivery and services.
Upstream inputs include seed strains and reference reagents, culture media and cell lines or eggs, single-use process kits, purification resins and QC assay reagents. As the industry shifts toward cell-based and genetic-engineering platforms, demand for high-reliability, batch-consistent, GMP-grade single-use materials has grown significantly; localization and multi-sourcing of critical inputs are strategic priorities to mitigate supply-chain disruption risk. Company reports show that strategic long-term partnerships between manufacturers and material suppliers, vertical integration of production capacity, and OEM/CMO models are important levers to secure annual supply and respond to emergent strain challenges. In short, upstream robustness underpins firms’ annual delivery capability and market credibility.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Seasonal Influenza Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Seasonal Influenza Vaccines.
The Seasonal Influenza Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Seasonal Influenza Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, by Technology and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Seasonal Influenza Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Technology and by regions.

Scope of Seasonal Influenza Vaccines Market Report

Report Metric Details
Report Name Seasonal Influenza Vaccines Market
Accounted market size in year US$ 9135 million
Forecasted market size in 2031 US$ 13501 million
CAGR 5.5%
Base Year year
Forecasted years 2026 - 2031
Segment by Type
  • Trivalent Influenza Vaccine
  • Quadrivalent Influenza Vaccine
Segment by Technology
  • Chicken Embryo Technology
  • Cell Culture Technology
  • Recombinant Technology
  • Adjuvant Vaccines
Segment by Administration
  • Injectable
  • Nasal Spray
Segment by Application
  • 6 Months to 3 Years
  • > 3 Years
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, KM Biologics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Seasonal Influenza Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Seasonal Influenza Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Seasonal Influenza Vaccines Market growing?

Ans: The Seasonal Influenza Vaccines Market witnessing a CAGR of 5.5% during the forecast period 2026-2031.

What is the Seasonal Influenza Vaccines Market size in 2031?

Ans: The Seasonal Influenza Vaccines Market size in 2031 will be US$ 13501 million.

Who are the main players in the Seasonal Influenza Vaccines Market report?

Ans: The main players in the Seasonal Influenza Vaccines Market are Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, KM Biologics

What are the Application segmentation covered in the Seasonal Influenza Vaccines Market report?

Ans: The Applications covered in the Seasonal Influenza Vaccines Market report are 6 Months to 3 Years, > 3 Years

What are the Type segmentation covered in the Seasonal Influenza Vaccines Market report?

Ans: The Types covered in the Seasonal Influenza Vaccines Market report are Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine

1 Seasonal Influenza Vaccines Market Overview
1.1 Product Definition
1.2 Seasonal Influenza Vaccines by Type
1.2.1 Global Seasonal Influenza Vaccines Market Value Comparison by Type (2024 VS 2031)
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Seasonal Influenza Vaccines by Technology
1.3.1 Global Seasonal Influenza Vaccines Market Value Comparison by Technology: 2024 VS 2031
1.3.2 Chicken Embryo Technology
1.3.3 Cell Culture Technology
1.3.4 Recombinant Technology
1.3.5 Adjuvant Vaccines
1.4 Seasonal Influenza Vaccines by Administration
1.4.1 Global Seasonal Influenza Vaccines Market Value Comparison by Administration: 2024 VS 2031
1.4.2 Injectable
1.4.3 Nasal Spray
1.5 Seasonal Influenza Vaccines by Application
1.5.1 Global Seasonal Influenza Vaccines Market Value by Application (2024 VS 2031)
1.5.2 6 Months to 3 Years
1.5.3 > 3 Years
1.6 Global Seasonal Influenza Vaccines Market Size Estimates and Forecasts
1.6.1 Global Seasonal Influenza Vaccines Revenue 2020-2031
1.6.2 Global Seasonal Influenza Vaccines Sales 2020-2031
1.6.3 Global Seasonal Influenza Vaccines Market Average Price (2020-2031)
1.7 Assumptions and Limitations
2 Seasonal Influenza Vaccines Market Competition by Manufacturers
2.1 Global Seasonal Influenza Vaccines Sales Market Share by Manufacturers (2020-2025)
2.2 Global Seasonal Influenza Vaccines Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Seasonal Influenza Vaccines Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Seasonal Influenza Vaccines, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Seasonal Influenza Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Seasonal Influenza Vaccines, Product Type & Application
2.7 Global Key Manufacturers of Seasonal Influenza Vaccines, Date of Enter into This Industry
2.8 Global Seasonal Influenza Vaccines Market Competitive Situation and Trends
2.8.1 Global Seasonal Influenza Vaccines Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Seasonal Influenza Vaccines Players Market Share by Revenue
2.8.3 Global Seasonal Influenza Vaccines Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Seasonal Influenza Vaccines Market Scenario by Region
3.1 Global Seasonal Influenza Vaccines Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Seasonal Influenza Vaccines Sales by Region: 2020-2031
3.2.1 Global Seasonal Influenza Vaccines Sales by Region: 2020-2025
3.2.2 Global Seasonal Influenza Vaccines Sales by Region: 2026-2031
3.3 Global Seasonal Influenza Vaccines Revenue by Region: 2020-2031
3.3.1 Global Seasonal Influenza Vaccines Revenue by Region: 2020-2025
3.3.2 Global Seasonal Influenza Vaccines Revenue by Region: 2026-2031
3.4 North America Seasonal Influenza Vaccines Market Facts & Figures by Country
3.4.1 North America Seasonal Influenza Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Seasonal Influenza Vaccines Sales by Country (2020-2031)
3.4.3 North America Seasonal Influenza Vaccines Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Seasonal Influenza Vaccines Market Facts & Figures by Country
3.5.1 Europe Seasonal Influenza Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Seasonal Influenza Vaccines Sales by Country (2020-2031)
3.5.3 Europe Seasonal Influenza Vaccines Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Seasonal Influenza Vaccines Market Facts & Figures by Region
3.6.1 Asia Pacific Seasonal Influenza Vaccines Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Seasonal Influenza Vaccines Sales by Region (2020-2031)
3.6.3 Asia Pacific Seasonal Influenza Vaccines Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Seasonal Influenza Vaccines Market Facts & Figures by Country
3.7.1 Latin America Seasonal Influenza Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Seasonal Influenza Vaccines Sales by Country (2020-2031)
3.7.3 Latin America Seasonal Influenza Vaccines Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Seasonal Influenza Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Seasonal Influenza Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Seasonal Influenza Vaccines Sales by Country (2020-2031)
3.8.3 Middle East and Africa Seasonal Influenza Vaccines Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Seasonal Influenza Vaccines Sales by Type (2020-2031)
4.1.1 Global Seasonal Influenza Vaccines Sales by Type (2020-2025)
4.1.2 Global Seasonal Influenza Vaccines Sales by Type (2026-2031)
4.1.3 Global Seasonal Influenza Vaccines Sales Market Share by Type (2020-2031)
4.2 Global Seasonal Influenza Vaccines Revenue by Type (2020-2031)
4.2.1 Global Seasonal Influenza Vaccines Revenue by Type (2020-2025)
4.2.2 Global Seasonal Influenza Vaccines Revenue by Type (2026-2031)
4.2.3 Global Seasonal Influenza Vaccines Revenue Market Share by Type (2020-2031)
4.3 Global Seasonal Influenza Vaccines Price by Type (2020-2031)
5 Segment by Application
5.1 Global Seasonal Influenza Vaccines Sales by Application (2020-2031)
5.1.1 Global Seasonal Influenza Vaccines Sales by Application (2020-2025)
5.1.2 Global Seasonal Influenza Vaccines Sales by Application (2026-2031)
5.1.3 Global Seasonal Influenza Vaccines Sales Market Share by Application (2020-2031)
5.2 Global Seasonal Influenza Vaccines Revenue by Application (2020-2031)
5.2.1 Global Seasonal Influenza Vaccines Revenue by Application (2020-2025)
5.2.2 Global Seasonal Influenza Vaccines Revenue by Application (2026-2031)
5.2.3 Global Seasonal Influenza Vaccines Revenue Market Share by Application (2020-2031)
5.3 Global Seasonal Influenza Vaccines Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Seasonal Influenza Vaccines Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 CSL
6.2.1 CSL Company Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.2.4 CSL Seasonal Influenza Vaccines Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GSK Seasonal Influenza Vaccines Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Viatris
6.4.1 Viatris Company Information
6.4.2 Viatris Description and Business Overview
6.4.3 Viatris Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Viatris Seasonal Influenza Vaccines Product Portfolio
6.4.5 Viatris Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.5.4 AstraZeneca Seasonal Influenza Vaccines Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Hualan Bio
6.6.1 Hualan Bio Company Information
6.6.2 Hualan Bio Description and Business Overview
6.6.3 Hualan Bio Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Hualan Bio Seasonal Influenza Vaccines Product Portfolio
6.6.5 Hualan Bio Recent Developments/Updates
6.7 Changchun Institute of Biological
6.7.1 Changchun Institute of Biological Company Information
6.7.2 Changchun Institute of Biological Description and Business Overview
6.7.3 Changchun Institute of Biological Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Changchun Institute of Biological Seasonal Influenza Vaccines Product Portfolio
6.7.5 Changchun Institute of Biological Recent Developments/Updates
6.8 Sinovac
6.8.1 Sinovac Company Information
6.8.2 Sinovac Description and Business Overview
6.8.3 Sinovac Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Sinovac Seasonal Influenza Vaccines Product Portfolio
6.8.5 Sinovac Recent Developments/Updates
6.9 BCHT
6.9.1 BCHT Company Information
6.9.2 BCHT Description and Business Overview
6.9.3 BCHT Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.9.4 BCHT Seasonal Influenza Vaccines Product Portfolio
6.9.5 BCHT Recent Developments/Updates
6.10 Jiangsu GDK
6.10.1 Jiangsu GDK Company Information
6.10.2 Jiangsu GDK Description and Business Overview
6.10.3 Jiangsu GDK Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Jiangsu GDK Seasonal Influenza Vaccines Product Portfolio
6.10.5 Jiangsu GDK Recent Developments/Updates
6.11 KM Biologics
6.11.1 KM Biologics Company Information
6.11.2 KM Biologics Description and Business Overview
6.11.3 KM Biologics Seasonal Influenza Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.11.4 KM Biologics Seasonal Influenza Vaccines Product Portfolio
6.11.5 KM Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Seasonal Influenza Vaccines Industry Chain Analysis
7.2 Seasonal Influenza Vaccines Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Seasonal Influenza Vaccines Production Mode & Process Analysis
7.4 Seasonal Influenza Vaccines Sales and Marketing
7.4.1 Seasonal Influenza Vaccines Sales Channels
7.4.2 Seasonal Influenza Vaccines Distributors
7.5 Seasonal Influenza Vaccines Customer Analysis
8 Seasonal Influenza Vaccines Market Dynamics
8.1 Seasonal Influenza Vaccines Industry Trends
8.2 Seasonal Influenza Vaccines Market Drivers
8.3 Seasonal Influenza Vaccines Market Challenges
8.4 Seasonal Influenza Vaccines Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Seasonal Influenza Vaccines Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Seasonal Influenza Vaccines Market Value by Technology, (US$ Million) & (2024 VS 2031)
 Table 3. Global Seasonal Influenza Vaccines Market Value by Administration, (US$ Million) & (2024 VS 2031)
 Table 4. Global Seasonal Influenza Vaccines Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 5. Global Seasonal Influenza Vaccines Market Competitive Situation by Manufacturers in 2024
 Table 6. Global Seasonal Influenza Vaccines Sales (K Units) of Key Manufacturers (2020-2025)
 Table 7. Global Seasonal Influenza Vaccines Sales Market Share by Manufacturers (2020-2025)
 Table 8. Global Seasonal Influenza Vaccines Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 9. Global Seasonal Influenza Vaccines Revenue Share by Manufacturers (2020-2025)
 Table 10. Global Market Seasonal Influenza Vaccines Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 11. Global Key Players of Seasonal Influenza Vaccines, Industry Ranking, 2022 VS 2023 VS 2024
 Table 12. Global Key Manufacturers of Seasonal Influenza Vaccines, Manufacturing Sites & Headquarters
 Table 13. Global Key Manufacturers of Seasonal Influenza Vaccines, Product Type & Application
 Table 14. Global Key Manufacturers of Seasonal Influenza Vaccines, Date of Enter into This Industry
 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 16. Global Seasonal Influenza Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Seasonal Influenza Vaccines as of 2024)
 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 18. Global Seasonal Influenza Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 19. Global Seasonal Influenza Vaccines Sales by Region (2020-2025) & (K Units)
 Table 20. Global Seasonal Influenza Vaccines Sales Market Share by Region (2020-2025)
 Table 21. Global Seasonal Influenza Vaccines Sales by Region (2026-2031) & (K Units)
 Table 22. Global Seasonal Influenza Vaccines Sales Market Share by Region (2026-2031)
 Table 23. Global Seasonal Influenza Vaccines Revenue by Region (2020-2025) & (US$ Million)
 Table 24. Global Seasonal Influenza Vaccines Revenue Market Share by Region (2020-2025)
 Table 25. Global Seasonal Influenza Vaccines Revenue by Region (2026-2031) & (US$ Million)
 Table 26. Global Seasonal Influenza Vaccines Revenue Market Share by Region (2026-2031)
 Table 27. North America Seasonal Influenza Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. North America Seasonal Influenza Vaccines Sales by Country (2020-2025) & (K Units)
 Table 29. North America Seasonal Influenza Vaccines Sales by Country (2026-2031) & (K Units)
 Table 30. North America Seasonal Influenza Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 31. North America Seasonal Influenza Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 32. Europe Seasonal Influenza Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 33. Europe Seasonal Influenza Vaccines Sales by Country (2020-2025) & (K Units)
 Table 34. Europe Seasonal Influenza Vaccines Sales by Country (2026-2031) & (K Units)
 Table 35. Europe Seasonal Influenza Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 36. Europe Seasonal Influenza Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 37. Asia Pacific Seasonal Influenza Vaccines Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 38. Asia Pacific Seasonal Influenza Vaccines Sales by Region (2020-2025) & (K Units)
 Table 39. Asia Pacific Seasonal Influenza Vaccines Sales by Region (2026-2031) & (K Units)
 Table 40. Asia Pacific Seasonal Influenza Vaccines Revenue by Region (2020-2025) & (US$ Million)
 Table 41. Asia Pacific Seasonal Influenza Vaccines Revenue by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Seasonal Influenza Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Latin America Seasonal Influenza Vaccines Sales by Country (2020-2025) & (K Units)
 Table 44. Latin America Seasonal Influenza Vaccines Sales by Country (2026-2031) & (K Units)
 Table 45. Latin America Seasonal Influenza Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Seasonal Influenza Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 47. Middle East and Africa Seasonal Influenza Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 48. Middle East and Africa Seasonal Influenza Vaccines Sales by Country (2020-2025) & (K Units)
 Table 49. Middle East and Africa Seasonal Influenza Vaccines Sales by Country (2026-2031) & (K Units)
 Table 50. Middle East and Africa Seasonal Influenza Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 51. Middle East and Africa Seasonal Influenza Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 52. Global Seasonal Influenza Vaccines Sales (K Units) by Type (2020-2025)
 Table 53. Global Seasonal Influenza Vaccines Sales (K Units) by Type (2026-2031)
 Table 54. Global Seasonal Influenza Vaccines Sales Market Share by Type (2020-2025)
 Table 55. Global Seasonal Influenza Vaccines Sales Market Share by Type (2026-2031)
 Table 56. Global Seasonal Influenza Vaccines Revenue (US$ Million) by Type (2020-2025)
 Table 57. Global Seasonal Influenza Vaccines Revenue (US$ Million) by Type (2026-2031)
 Table 58. Global Seasonal Influenza Vaccines Revenue Market Share by Type (2020-2025)
 Table 59. Global Seasonal Influenza Vaccines Revenue Market Share by Type (2026-2031)
 Table 60. Global Seasonal Influenza Vaccines Price (US$/Unit) by Type (2020-2025)
 Table 61. Global Seasonal Influenza Vaccines Price (US$/Unit) by Type (2026-2031)
 Table 62. Global Seasonal Influenza Vaccines Sales (K Units) by Application (2020-2025)
 Table 63. Global Seasonal Influenza Vaccines Sales (K Units) by Application (2026-2031)
 Table 64. Global Seasonal Influenza Vaccines Sales Market Share by Application (2020-2025)
 Table 65. Global Seasonal Influenza Vaccines Sales Market Share by Application (2026-2031)
 Table 66. Global Seasonal Influenza Vaccines Revenue (US$ Million) by Application (2020-2025)
 Table 67. Global Seasonal Influenza Vaccines Revenue (US$ Million) by Application (2026-2031)
 Table 68. Global Seasonal Influenza Vaccines Revenue Market Share by Application (2020-2025)
 Table 69. Global Seasonal Influenza Vaccines Revenue Market Share by Application (2026-2031)
 Table 70. Global Seasonal Influenza Vaccines Price (US$/Unit) by Application (2020-2025)
 Table 71. Global Seasonal Influenza Vaccines Price (US$/Unit) by Application (2026-2031)
 Table 72. Sanofi Company Information
 Table 73. Sanofi Description and Business Overview
 Table 74. Sanofi Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 75. Sanofi Seasonal Influenza Vaccines Product
 Table 76. Sanofi Recent Developments/Updates
 Table 77. CSL Company Information
 Table 78. CSL Description and Business Overview
 Table 79. CSL Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 80. CSL Seasonal Influenza Vaccines Product
 Table 81. CSL Recent Developments/Updates
 Table 82. GSK Company Information
 Table 83. GSK Description and Business Overview
 Table 84. GSK Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 85. GSK Seasonal Influenza Vaccines Product
 Table 86. GSK Recent Developments/Updates
 Table 87. Viatris Company Information
 Table 88. Viatris Description and Business Overview
 Table 89. Viatris Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Viatris Seasonal Influenza Vaccines Product
 Table 91. Viatris Recent Developments/Updates
 Table 92. AstraZeneca Company Information
 Table 93. AstraZeneca Description and Business Overview
 Table 94. AstraZeneca Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 95. AstraZeneca Seasonal Influenza Vaccines Product
 Table 96. AstraZeneca Recent Developments/Updates
 Table 97. Hualan Bio Company Information
 Table 98. Hualan Bio Description and Business Overview
 Table 99. Hualan Bio Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 100. Hualan Bio Seasonal Influenza Vaccines Product
 Table 101. Hualan Bio Recent Developments/Updates
 Table 102. Changchun Institute of Biological Company Information
 Table 103. Changchun Institute of Biological Description and Business Overview
 Table 104. Changchun Institute of Biological Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 105. Changchun Institute of Biological Seasonal Influenza Vaccines Product
 Table 106. Changchun Institute of Biological Recent Developments/Updates
 Table 107. Sinovac Company Information
 Table 108. Sinovac Description and Business Overview
 Table 109. Sinovac Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 110. Sinovac Seasonal Influenza Vaccines Product
 Table 111. Sinovac Recent Developments/Updates
 Table 112. BCHT Company Information
 Table 113. BCHT Description and Business Overview
 Table 114. BCHT Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 115. BCHT Seasonal Influenza Vaccines Product
 Table 116. BCHT Recent Developments/Updates
 Table 117. Jiangsu GDK Company Information
 Table 118. Jiangsu GDK Description and Business Overview
 Table 119. Jiangsu GDK Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 120. Jiangsu GDK Seasonal Influenza Vaccines Product
 Table 121. Jiangsu GDK Recent Developments/Updates
 Table 122. KM Biologics Company Information
 Table 123. KM Biologics Description and Business Overview
 Table 124. KM Biologics Seasonal Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 125. KM Biologics Seasonal Influenza Vaccines Product
 Table 126. KM Biologics Recent Developments/Updates
 Table 127. Key Raw Materials Lists
 Table 128. Raw Materials Key Suppliers Lists
 Table 129. Seasonal Influenza Vaccines Distributors List
 Table 130. Seasonal Influenza Vaccines Customers List
 Table 131. Seasonal Influenza Vaccines Market Trends
 Table 132. Seasonal Influenza Vaccines Market Drivers
 Table 133. Seasonal Influenza Vaccines Market Challenges
 Table 134. Seasonal Influenza Vaccines Market Restraints
 Table 135. Research Programs/Design for This Report
 Table 136. Key Data Information from Secondary Sources
 Table 137. Key Data Information from Primary Sources
 Table 138. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Seasonal Influenza Vaccines
 Figure 2. Global Seasonal Influenza Vaccines Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Seasonal Influenza Vaccines Market Share by Type: 2024 & 2031
 Figure 4. Trivalent Influenza Vaccine Product Picture
 Figure 5. Quadrivalent Influenza Vaccine Product Picture
 Figure 6. Global Seasonal Influenza Vaccines Market Value by Technology, (US$ Million) & (2020-2031)
 Figure 7. Global Seasonal Influenza Vaccines Market Share by Technology: 2024 VS 2031
 Figure 8. Chicken Embryo Technology Product Picture
 Figure 9. Cell Culture Technology Product Picture
 Figure 10. Recombinant Technology Product Picture
 Figure 11. Adjuvant Vaccines Product Picture
 Figure 12. Global Seasonal Influenza Vaccines Market Value by Administration, (US$ Million) & (2020-2031)
 Figure 13. Global Seasonal Influenza Vaccines Market Share by Administration: 2024 VS 2031
 Figure 14. Injectable Product Picture
 Figure 15. Nasal Spray Product Picture
 Figure 16. Global Seasonal Influenza Vaccines Market Value by Application (2020-2031) & (US$ Million)
 Figure 17. Global Seasonal Influenza Vaccines Market Share by Application: 2024 & 2031
 Figure 18. 6 Months to 3 Years
 Figure 19. > 3 Years
 Figure 20. Global Seasonal Influenza Vaccines Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 21. Global Seasonal Influenza Vaccines Market Size (2020-2031) & (US$ Million)
 Figure 22. Global Seasonal Influenza Vaccines Sales (2020-2031) & (K Units)
 Figure 23. Global Seasonal Influenza Vaccines Average Price (US$/Unit) & (2020-2031)
 Figure 24. Seasonal Influenza Vaccines Report Years Considered
 Figure 25. Seasonal Influenza Vaccines Sales Share by Manufacturers in 2024
 Figure 26. Global Seasonal Influenza Vaccines Revenue Share by Manufacturers in 2024
 Figure 27. Global 5 and 10 Largest Seasonal Influenza Vaccines Players: Market Share by Revenue in Seasonal Influenza Vaccines in 2024
 Figure 28. Seasonal Influenza Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 29. Global Seasonal Influenza Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 30. North America Seasonal Influenza Vaccines Sales Market Share by Country (2020-2031)
 Figure 31. North America Seasonal Influenza Vaccines Revenue Market Share by Country (2020-2031)
 Figure 32. U.S. Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Canada Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Europe Seasonal Influenza Vaccines Sales Market Share by Country (2020-2031)
 Figure 35. Europe Seasonal Influenza Vaccines Revenue Market Share by Country (2020-2031)
 Figure 36. Germany Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. France Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. U.K. Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Italy Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Russia Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Asia Pacific Seasonal Influenza Vaccines Sales Market Share by Region (2020-2031)
 Figure 42. Asia Pacific Seasonal Influenza Vaccines Revenue Market Share by Region (2020-2031)
 Figure 43. China Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Japan Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. South Korea Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. India Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Australia Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Taiwan Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Indonesia Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Thailand Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Malaysia Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Philippines Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Latin America Seasonal Influenza Vaccines Sales Market Share by Country (2020-2031)
 Figure 54. Latin America Seasonal Influenza Vaccines Revenue Market Share by Country (2020-2031)
 Figure 55. Mexico Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Brazil Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Argentina Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Middle East and Africa Seasonal Influenza Vaccines Sales Market Share by Country (2020-2031)
 Figure 59. Middle East and Africa Seasonal Influenza Vaccines Revenue Market Share by Country (2020-2031)
 Figure 60. Turkey Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 61. Saudi Arabia Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 62. U.A.E Seasonal Influenza Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 63. Global Sales Market Share of Seasonal Influenza Vaccines by Type (2020-2031)
 Figure 64. Global Revenue Market Share of Seasonal Influenza Vaccines by Type (2020-2031)
 Figure 65. Global Seasonal Influenza Vaccines Price (US$/Unit) by Type (2020-2031)
 Figure 66. Global Sales Market Share of Seasonal Influenza Vaccines by Application (2020-2031)
 Figure 67. Global Revenue Market Share of Seasonal Influenza Vaccines by Application (2020-2031)
 Figure 68. Global Seasonal Influenza Vaccines Price (US$/Unit) by Application (2020-2031)
 Figure 69. Seasonal Influenza Vaccines Value Chain
 Figure 70. Channels of Distribution (Direct Vs Distribution)
 Figure 71. Bottom-up and Top-down Approaches for This Report
 Figure 72. Data Triangulation
 Figure 73. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture

SIMILAR REPORTS